Quantification of diffuse myocardial fibrosis by cardiac magnetic resonance imaging
Not Applicable
Recruiting
- Conditions
- I50Heart failure
- Registration Number
- DRKS00006225
- Lead Sponsor
- Medizinische Universität WienUniversitätsklinik für Innere Medizin IIAbteilung für Kardiologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
= 18 years old
informed consent
Symptoms of heart failure (NYHA>1)
Transthoracic echocardiography:
LVEF>50%
LVEDVI<97ml/m2
E/E’>15
15>E/e’>8 and NT-proBNP >220pg/ml
Exclusion Criteria
1. Unwillingness to participate
2. LVEF<50%
3. Significant valvular lesion
4. Congenital heart disease
5. Significant coronary artery disease
6. Diastolic dysfunction without symptoms of heart failure
7. Severe renal impairment (GFR<30ml/min)
8. Pregnancy
9. Asthma bronchiale or COPD with a FEV1<60%
10. Restrictive lung disease with a total lung capacity <60%
11. Severe abnormalities of thorax, lungs or diaphragm
12. Severe abnormalities in blood gas analysis: SaO2<88% or PaO2<55mmHg
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantification of diffuse myocardial fibrosis by CMR using T1-mapping will be compared with biopsies taken during heart catheterization.
- Secondary Outcome Measures
Name Time Method